Latest news and analysis for Ultragenyx Pharmaceutical (RARE).
Ultragenyx Pharmaceutical (RARE) is in the spotlight following robust data on its gene therapy UX111, signaling significant progress for Sanfilippo syndrome.
Yahoo Finance · 4 min read
RARE reports a 20% revenue increase in 2025 and outlines its strategy for achieving profitability by 2027. Explore the details in this analysis.
Yahoo Finance · 3 min read
RARE shares surged despite posting a wider-than-expected Q4 loss. The strategic restructuring plan aims for profitability by 2027.
Yahoo Finance · 3 min read